Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovalpituzumab Tesirine Extension Study
NCT03543358Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rovalpituzumab tesirine in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Number of Participants Receiving Treatment or Retreatment Who Experience a Treatment-Emergent Adverse Event up to 5 years. Started Sep 2018; status: completed.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on NCT03543358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03543358.